CD163 and neoplasm: In the study of Dias Costa et al., the increase of CD163− macrophages and the location of CD163− macrophages near the tumor cells, was also associated with a better response to neoadjuvant FOLFIRINOX and with a better survival (Dias Costa et al. 2022).